Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016
Cited by 4,675 works. doi:10.1016/s0140-6736(16)32517-x Open-access PDF
Authors
- Achim Rittmeyer
- Fabrice Barlési
- Daniel Waterkamp
- Keunchil Park
- Fortunato Ciardiello
- Joachim von Pawel
- Shirish M. Gadgeel
- Toyoaki Hida
- Dariusz Mirosław Kowalski
- Manuel Cobo
- Diego Luigi Cortinovis
- Joseph W. Leach
- Jonathan A. Polikoff
- Carlos H. Barrios
- Fairooz F. Kabbinavar
- Osvaldo Arén Frontera
- Filippo de Marinis
- Hande Turna
- Jong-Seok Lee
- Marcus D. Ballinger
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial